Anthem Blue Cross and Blue Shield

Precertification Required on Part B New Injectables

Anthem Blue Cross and Blue Shield is adding the following new injectable drugs to the 2015 Medicare Advantage list of Part B Injectables / Infusible requiring precertification. **As of October 1, 2015 providers must call for precertification of these drugs.**

1. **Entyvio (vedolizumab):** a monoclonal antibody that is a specific integrin receptor antagonist used for the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adult patients. (C9026)
2. **Cyramza (Ramucirumab):** used in the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression during or after treatment with fluoropyrimidine-or platinum-containing chemotherapy (C9025).

This update to the 2015 precertification requirement applies to all the following Medicare Advantage plans.

53993WPSENMUB 06/10/15